Commercial Services and Supplies
Company Overview of Department of Health
Department of Health oversees the strategic planning, policy regulation, funding, and research activities of the public health system. The institution is based in London, United Kingdom.
London, SW1A 2NS
Key Executives for Department of Health
Director General of Communications and Architect of Change 4 Life Healthy Living Campaign
Deputy Chief Nursing Officer
Chairman of Pharmacy Programme Board
Director of Health Protection
Compensation as of Fiscal Year 2016.
Department of Health Key Developments
Department Of Health Presents at FT Global Pharmaceutical and Biotechnology Conference 2015, Nov-16-2015 10:50 AM
Sep 29 15
Department Of Health Presents at FT Global Pharmaceutical and Biotechnology Conference 2015, Nov-16-2015 10:50 AM. Venue: Marriott Hotel, Grosvenor Square, London W1K 6JP, United Kingdom. Speakers: Dame Sally Davies, Chief Medical and Chief Scientific Officer.
Department Of Health Reaches Agreement with GlaxoSmithKline plc on Meningitis Vaccine Bexsero
Mar 30 15
GlaxoSmithKline has reached an agreement with the United Kingdom's Department of Health (DoH) over the pricing of the firm's meningitis B vaccine Bexsero (meningococcal group-B vaccine [rDNA, component, adsorbed]). The vaccine will be added to the national childhood immunisation scheme, and babies will be immunised first at the age of two months, followed by two more doses.
GlaxoSmithKline Enters into Agreement with the UK Department of Health
Mar 30 15
GlaxoSmithKline (GSK) has entered into an agreement with the UK Department of Health to introduce a new vaccine to prevent meningitis caused by meningococcal group B bacteria for all babies in the country. The meningitis B vaccine will be introduced as part of the National Health Service's (NHS) NHS immunization program, which is scheduled to be initiated in September 2015. The vaccine will now be added to the national childhood immunization program, while babies will receive the first vaccine at two months old, followed by two further doses. The agreement offers fair value for the NHS and allows a reasonable return for the company to ensure that it can continue to invest in creating new treatments and vaccines.
Similar Private Companies By Industry
Recent Private Companies Transactions
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries